Johnson & Johnson (NYSE:JNJ) Shares Bought by CGN Advisors LLC

CGN Advisors LLC raised its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 36.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,071 shares of the company’s stock after purchasing an additional 4,599 shares during the quarter. CGN Advisors LLC’s holdings in Johnson & Johnson were worth $3,016,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of JNJ. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the last quarter. State Street Corp increased its stake in Johnson & Johnson by 0.6% during the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after buying an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Johnson & Johnson by 3.3% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after buying an additional 805,831 shares during the period. Legal & General Group Plc increased its stake in Johnson & Johnson by 2.3% during the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after buying an additional 421,779 shares during the period. Finally, FMR LLC increased its stake in Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after buying an additional 3,229,032 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 25th. Citigroup increased their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. SVB Leerink dropped their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Guggenheim began coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective on the stock. Finally, StockNews.com began coverage on shares of Johnson & Johnson in a report on Thursday. They issued a “strong-buy” rating for the company. Seven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Trading Down 1.1 %

Shares of Johnson & Johnson stock opened at $152.38 on Friday. Johnson & Johnson has a fifty-two week low of $150.71 and a fifty-two week high of $186.69. The firm has a market cap of $396.84 billion, a PE ratio of 22.61, a P/E/G ratio of 2.65 and a beta of 0.54. The business’s fifty day moving average is $161.97 and its two-hundred day moving average is $167.88. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The company had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same quarter in the prior year, the company posted $2.13 EPS. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.5 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.97%. Johnson & Johnson’s payout ratio is 67.06%.

Insider Transactions at Johnson & Johnson

In other news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.